Glienicke/Nordbahn, Germany

Jörg Willuda

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 10.3

ph-index = 2

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: **Jörg Willuda: A Pioneer in Antibody Research**

Introduction

Jörg Willuda is a noteworthy inventor based in Glienicke/Nordbahn, Germany, recognized for his innovations in the field of biopharmaceuticals. With a solid portfolio comprising five patents, his work primarily focuses on the development of antibody therapies aimed at treating various cancers and disorders.

Latest Patents

Among his latest contributions to the realm of medicine, one significant patent involves a pharmaceutical combination of anti-CEACAM6 and TIM3 antibodies. This innovative disclosure discusses combinations of component A, the anti-CEACAM6 antibody TPP-3310, and component B, an anti-TIM-3 antibody such as cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367, or INCAGN-2390. Another significant patent pertains to anti-CEACAM6 antibodies and their uses, which details recombinant antigen-binding regions and methods to generate antibodies specific to human CEACAM6, while avoiding cross-reactivity with similar human proteins. These antibodies hold potential for treating cancer and various conditions linked with the expression of CEACAM6, alongside providing nucleic acid sequences, vectors, and pharmaceutical compositions.

Career Highlights

Throughout his career, Jörg Willuda has collaborated with eminent organizations, notably the Deutsches Krebsforschungszentrum (German Cancer Research Center) and Seattle Genetics, Inc. His inventive contributions have made substantial impacts on the development of therapeutic antibodies and shed light on novel treatment methodologies.

Collaborations

Willuda's work has been significantly enhanced through collaborations with esteemed professionals such as Sven Golfier and Uwe Gritzan. These partnerships have allowed for the fusion of diverse expertise, further pushing the boundaries of research in biopharmaceutical applications.

Conclusion

In summary, Jörg Willuda exemplifies a remarkable inventor whose work continues to influence the medical research landscape. His patents showcase innovative approaches to antibody therapies, providing valuable tools in the fight against cancer and related disorders. As the field of biopharmaceuticals evolves, Willuda's contributions will likely remain at the forefront of therapeutic advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…